Other cancers, including prostate cancer, colon cancer, and non-small cell lung carcinoma (NSCLC), have also demonstrated how NF-κB -induced expression of PD-L1 may be an attractive target in cancer therapeutics [96, 104]. Here, CD274 is linked to cancer.